Sequestosome 1 (SQSTM1, A170, EBI3-associated Protein of 60kD, EBIAP, ORCA, Oxidative Stress Induced-like, OSIL, p60, p62B, Paget Disease of Bone 3, PDB3, Phosphotyrosine-independent Ligand for the Lck SH2 Domain of 62kD, Phosphotyrosine-independent Ligan

Adapter protein which binds ubiquitin and may regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1. May play a role in titin/TTN downstream signaling in muscle cells. May regulate signaling cascades through ubiquitination. May be involved in cell differentiation, apoptosis, immune response and regulation of K(+) channels. SUBUNIT: Homooligomer or heterooligomer; may form homotypic arrays. Interacts directly with PRKCI and PRKCZ (Probable). Forms ternary complexes with PRKCZ and KCNAB2 or PRKCZ and GABBR3. Also interacts with KCNAB1, GABRR1, GABRR2 and GABRR3. Forms an NGF-induced complex with IKBKB, PRKCI and TRAF6. Interacts with EBI3, LCK, RASA1, PRKCZ, PRKCI, NR2F2, NTRK1, NTRK2, NTRK3, NBR1, MAP2K5, TRIM55 and MAPKAPK5. Interacts with the proteasome subunits PSMD4 and PSMC2. Interacts with K63-polyubiquitinated MAPT/TAU. Interacts with IKBKB through PRKCZ and PRKCI. Interacts with NGFR through TRAF6 and bridges that complex to NTRK1. Forms a complex with MAP2K5 and PRKCZ or PRKCI. Component of a ternary complex with PAWR and PRKCZ. Upon TNF-alpha stimulation, interacts with RIPK1 problably bridging IKBKB to the TNF-R1 complex composed of TNF-R1/TNFRSF1A, TRADD and RIPK1. Forms a complex with JUB/Ajuba, PRKCZ and TRAF6. INTERACTION: P54725:RAD23A; NbExp=1; IntAct=EBI-307104, EBI-746453.\n\nTissue Specificity: Ubiquitously expressed. \n\nInduction: By proteasomal inhibitor PSI and prostaglandin J2 (PGJ2) (at protein level). By Phorbol 12-myristate 13-acetate (PMA). The UBA domain binds specifically 'Lys-63'-linked polyubiquitin chains of polyubiquitinated substrates. Mediates the interaction with TRIM55. The OPR domain mediates homooligomerization and interactions with PRKCZ, PRKCI, MAP2K5 and NBR1. DOMAIN: The ZZ-type zinc finger mediates the interaction with RIPK1. May be phosphorylated by PRKCZ. Phosphorylated in vitro by TTN. \n\nDefects in SQSTM1 are a cause of sporadic and familial Paget disease of bone (PDB). PDB is a metabolic bone disease affecting the axial skeleton and characterized by focal areas of increased and disorganized bone turn-over due to activated osteoclasts. Manifestations of the disease include bone pain, deformity, pathological fractures, deafness, neurological complications and increased risk of osteosarcoma. PDB is a chronic disease affecting 2 to 3% of the population above the age of 40 years. \n\nCellular Localization:\nCytoplasm. Sarcomere. Endosome; late endosome. Nucleus. In cardiac muscles localizes to the sarcomeric band. Localizes to late endosomes. May also localize to the nucleus. Accumulates in neurofibrillary tangles and in Lewy bodies of neurons from individuals with Alzheimer and Parkinson disease respectively. Enriched in Rosenthal fibers of pilocytic astrocytoma. In liver cells, accumulates in Mallory bodies associated with alcoholic hepatitis, Wilson disease, indian childhood cirrhosis and in hyaline bodies associated with hepatocellular carcinoma. \n\nAlternative Products:\n2 named isoforms produced by alternative splicing.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile 40-50% glycerol and store at -20 degrees C. Reconstituted product is stable for 3 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S0961-50

Size

100ul

Hosts

Rabbit

Reactivities

Mouse, Rat, Bov

Form

Supplied as a lyophilized powder. Reconstitute in 100ul of sterile water. Centrifuge to remove any insoluble material.

P Type

Pab

Purity

Serum

References

1. Devergne O, et al. J. Virol. 70:1143-1153(1996). ; 2. Joung I, et al. Proc. Natl. Acad. Sci. U.S.A. 93:5991-5995(1996). ; 3. Vadlamudi R.K., Shin J. FEBS Lett. 435:138-142(1998). ; 4. Stumptner C, et al. Am. J. Pathol. 154:1701-1710(1999). ; 5.Park I, et al. Proc. Natl. Acad. Sci. U.S.A. 92:12338-12342(1995). ; 6.Vadlamudi R.K, et al. J. Biol. Chem. 271:20235-20237(1996). ; 7. Marcus S.L, et al. J. Biol. Chem. 271:27197-27200(1996). ; 8.Hocking L.J, et al.J. Bone Miner. Res. 19:1013-1017(2004). ; 9.Good D.A, et al. Bone 35:277-282(2004). ; 10.Ciani B, et al. J. Biol. Chem. 278:37409-37412(2003).

Additional Info

Species Crossreactivity: This antibody is expected to recognize p60 in mouse, rat and bovine. See the immunogen field also.